A Real-World Study of the Perceived Emotional and Social Experiences Related to Antifibrotic Therapy in Patients With IPF and PPF: A Cross-Sectional Web-Based Survey
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks
• Patients capable of responding to a self-administered questionnaire
Locations
Other Locations
Japan
Nippon Boehringer Ingelheim Co., Ltd.
RECRUITING
Tokyo
Contact Information
Primary
Boehringer Ingelheim
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127
Time Frame
Start Date: 2026-08-01
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 100
Treatments
Japanese patients with IPF/PPF
Related Therapeutic Areas
Sponsors
Leads: Boehringer Ingelheim